

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

437-NF-03

Claims:

1. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid of the formula


5



10


2. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

15



- 3 A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula


20



25

4. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula


30



437-NF-03


5. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

5




- 10 6. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

15




- 20 7. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

25




- 30 8. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



437-NF-03


9. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

5




10. A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula

15




11. A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula V

20




which comprises reacting a 4- (1H- benzo[d] imidazol-2-yl) phenol of the formula I,

25



- with N- [4-(n- bromoalkyloxy)-5- methoxy-2- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II

30




28

437-NF-03


in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {4- (1*H*- benzo [d] imidazo- 2 yl) phenoxy} alkyl - oxy- 5 methoxy- 2-nitrobenzoyl} pyrrolidine-2- carboxaldehyde diethyl thioacetal III

5



10 where "n" is 3 to 5, reducing said compound of formula III with $SnCl_2 \cdot 2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating the (2S)-N- {n- 4- (1*H*- benzo [d] imidazo- 2 yl) phenoxy} alkyl]-oxy- 5- methoxy- 2- aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal of the formula IV


15




20 where n is 3 to 5 by known methods, reacting the said amino compound of formula IV with conventional deprotecting agents in to produce pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula V, wherein "n" is as defined above.

12. A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula IX

25




30 which comprises reacting a 4- [6-4- methylhexahydro- 1- pyrazinyl)- 1*H* - benzo[imidazol- 2- yl] phenol VI




437-NF-03


with N- [4-(n- bromoalkoxy)-5- methoxy-2- nitrobenzo-yl] pyrrolidine- 2-
carboxaldehyde diethyl thio acetal of formula II



in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-
N- {n- (4- [6-4- methylhexahydro-1- pyrazinyl)- 1H- benzo [d] imidazol- 2-yl]
phenoxy] alkyl-oxy- 5- methoxy-2- nitrobenzoy pyrrolidine-2- carboxaldehyde diethyl
thioacetal VII




where "n" is 3 to 5, reducing said compound of formula VII with $SnCl_2 \cdot 2H_2O$ in the
presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n- (4- [6-(4-
methylhexahydro-1- pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenoxy] alkyl)-o xy-
5- methoxy -2- aminobenzoy} pyrrolidine-2- carboxaldehyde diethyl thioacetal VIII



and reacting the said amino compound of formula VIII with conventional deprotecting
agents in to produce pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula IX.
wherein "n".


13. A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of
formula XIII



437-NF-03


which comprises reacting a 4- [6-(4- ethylhexahydro- 1- pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenol X

5




with N- [4-(n- bromoalkoxy)-5- methoxy-2- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II

10



in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)- N- {n- (4- [6-4- ethylhexahydro-1- pyrazinyl)- H- benzo [d] imidazol-2- yl] phenoxy } alkyl] - oxy- 5- methoxy- 2- nitrobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal XI


15



20

where "n" is 3 to 5, reducing said compound of formula XI with $SnCl_2 \cdot 2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n-(4-[6-(4-ethylhexahydro-1- pyrazinyl)-1H - benzo[d] imidazol-2- yl] phenoxy} alkyl)- oxy-5- methoxy-2- aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal XII where n is 3 to 5

25



30

and reacting the said amino compound of formula XII with conventional deprotecting agents to produce pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula XIII wherein "n" is as defined above.

437-NF-03

14. Use of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in anyone of claims 1 to 10 for the preparation of medicament useful for treating tumours.

15. A pharmaceutical composition for use as antitumour agents comprising of an effective amount of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as
5 claimed in any one of claims 1 to 10.

16. A method of treating a mammal which comprises administering an effective amount of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in any one of claims 1 to 10.

17. A method of treating a mammal, which comprises administering an effective
10 amount of a pharmaceutical composition as claimed in claim 15.

15

20

25

30